Pindolol

Beta-blockers are a classic category of drugs in the field of cardiovascular disease treatment. Among them, pindolol, which has both non-selective β-receptor blocking effect and intrinsic sympathomimetic activity, has unique therapeutic advantages in clinical application. Its mechanism of action is to competitively block adrenergic β-receptors, reduce myocardial contractility and slow down heart rate. Meanwhile, due to the presence of intrinsic sympathomimetic activity, its inhibitory effect on heart rate and myocardial function is weaker than that of similar drugs without sympathomimetic activity such as propranolol. It is mainly used for the treatment of mild to moderate hypertension, angina pectoris, sinus tachycardia, ventricular premature beats and other conditions, and is especially suitable for cardiovascular disease patients with combined risk of bradycardia or asthma tendency.

At present, the global prevalence of cardiovascular diseases continues to rise, driving the steady expansion of market demand for beta-blocker APIs. In 2023, the global market size of pindolol-related preparations was approximately USD 120 million, with a compound annual growth rate of 3.1% in the past three years. In terms of competitive landscape, European and Indian pharmaceutical companies are the main suppliers of this API. At present, there are a small number of domestic enterprises with large-scale production capacity, and the market supply concentration is relatively high. With the continuous expansion of the domestic hypertensive patient population, the demand for pindolol API shows a steady upward trend.

The original research enterprise of pindolol is Novartis, with the original brand name Visken. The core compound patent in the US market expired in 1986, and the relevant preparation patents in the EU also expired around 1990. The main dosage forms approved by the original research are tablets, with specifications of 5mg and 10mg, and the original research products have been included in the FDA Reference Listed Drug Catalog. At present, no pindolol preparation products have been approved for marketing in China, and there is no publicly available A-state registration number of pindolol in the CDE API registration database. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full range of pindolol impurity reference standards, covering the research needs of the whole chain of synthesis process and degradation products. Most products are available from stock, and stock orders placed before 16:00 can be shipped on the same day. All reference standards comply with the pharmacopoeia of China, FDA and other national pharmaceutical regulatory regulations, and can provide stable and compliant reference standard support for the R&D and quality research stages of APIs and preparations.